DK0910365T3 - Væksthæmning og udslettelse af faste tumorer ved at anvende en prolactinmodulator og en fotosensibilisator - Google Patents
Væksthæmning og udslettelse af faste tumorer ved at anvende en prolactinmodulator og en fotosensibilisatorInfo
- Publication number
- DK0910365T3 DK0910365T3 DK97922668T DK97922668T DK0910365T3 DK 0910365 T3 DK0910365 T3 DK 0910365T3 DK 97922668 T DK97922668 T DK 97922668T DK 97922668 T DK97922668 T DK 97922668T DK 0910365 T3 DK0910365 T3 DK 0910365T3
- Authority
- DK
- Denmark
- Prior art keywords
- photosensitizer
- prolactin
- obliteration
- growth inhibition
- solid tumors
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 108010057464 Prolactin Proteins 0.000 title abstract 3
- 229940097325 prolactin Drugs 0.000 title abstract 3
- 239000003504 photosensitizing agent Substances 0.000 title abstract 2
- 102000003946 Prolactin Human genes 0.000 title 1
- 230000009036 growth inhibition Effects 0.000 title 1
- 241000124008 Mammalia Species 0.000 abstract 3
- 108010051696 Growth Hormone Proteins 0.000 abstract 2
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 abstract 2
- 102100024819 Prolactin Human genes 0.000 abstract 2
- 102100038803 Somatotropin Human genes 0.000 abstract 2
- 239000000122 growth hormone Substances 0.000 abstract 2
- 229960003987 melatonin Drugs 0.000 abstract 2
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000033764 rhythmic process Effects 0.000 abstract 1
- 241000894007 species Species 0.000 abstract 1
- 210000004881 tumor cell Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Radiation-Therapy Devices (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1661996P | 1996-05-01 | 1996-05-01 | |
| PCT/US1997/007577 WO1997040829A1 (en) | 1996-05-01 | 1997-04-15 | Growth inhibition and eradication of solid tumors using neuroendocrine resetting therapy and photodynamic therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK0910365T3 true DK0910365T3 (da) | 2003-10-20 |
Family
ID=21778086
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK97922668T DK0910365T3 (da) | 1996-05-01 | 1997-04-15 | Væksthæmning og udslettelse af faste tumorer ved at anvende en prolactinmodulator og en fotosensibilisator |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20010049350A1 (da) |
| EP (1) | EP0910365B1 (da) |
| JP (1) | JP2000509398A (da) |
| AT (1) | ATE243513T1 (da) |
| CA (1) | CA2253207C (da) |
| DE (1) | DE69723077T2 (da) |
| DK (1) | DK0910365T3 (da) |
| ES (1) | ES2205215T3 (da) |
| WO (1) | WO1997040829A1 (da) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7390668B2 (en) * | 1996-10-30 | 2008-06-24 | Provectus Pharmatech, Inc. | Intracorporeal medicaments for photodynamic treatment of disease |
| CA2375865C (en) * | 1999-06-03 | 2009-08-18 | The General Hospital Corporation | Treatment and analysis of proliferative disorders |
| DE10229456A1 (de) * | 2002-07-01 | 2004-02-05 | Wank, Rudolf, Prof. Dr.med. | Verwendung von Dopamin-Rezeptor-Agonisten zur Behandlung von Hautgeschwülsten und Warzen |
| US20090281518A1 (en) * | 2006-09-13 | 2009-11-12 | Koninklijke Philips Electronics N.V. | Device for automatic adjustment of the dose of melatonin and/or delivery of melatonin |
| CN101754753A (zh) * | 2007-05-24 | 2010-06-23 | 纽约市哥伦比亚大学托管会 | 褪黑素的持久释放配方 |
| US9724069B2 (en) * | 2009-12-22 | 2017-08-08 | Biolitec Unternehmensbeteiligungs Ii Ag | Tissue resection under image guidance/control |
| US8759289B2 (en) | 2010-02-03 | 2014-06-24 | Orbis Health Solutions Llc | Method for sensitizing cancer stem cells to cancer therapy |
| WO2011149962A1 (en) | 2010-05-24 | 2011-12-01 | The Trustees Of Columbia University In The City Of New York | Mutant ngal proteins and uses thereof |
| WO2014081980A2 (en) * | 2012-11-21 | 2014-05-30 | The Trustees Of Columbia University In The City Of New York | Mutant ngal proteins and uses thereof |
| EP3925610A1 (en) | 2016-04-20 | 2021-12-22 | VeroScience LLC | Composition and method for treating metabolic disorders |
| HRP20241365T1 (hr) | 2017-10-18 | 2024-12-20 | Veroscience Llc | Poboljšane formulacije bromokriptina |
| US11607455B2 (en) | 2019-09-23 | 2023-03-21 | Veroscience Llc | Method for inducing tumor regression |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH507249A (de) * | 1968-05-31 | 1971-05-15 | Sandoz Ag | Verfahren zur Herstellung von 2-Brom-a-ergokryptin |
| US4649151A (en) * | 1982-09-27 | 1987-03-10 | Health Research, Inc. | Drugs comprising porphyrins |
| US5585347A (en) * | 1988-05-10 | 1996-12-17 | Ergo Science Incorporated | Methods for the determination and adjustment of prolactin daily rhythms |
| US5344832A (en) * | 1990-01-10 | 1994-09-06 | The Board Of Supervisors Of Louisiana University And Agricultural And Mechanical College | Method for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia and hyperglycemia in vertebrates |
| US5468755A (en) * | 1988-05-10 | 1995-11-21 | The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Therapeutic process for the treatment of the pathologies of Type II diabetes |
| CA2030174C (en) * | 1990-01-10 | 1996-12-24 | Anthony H. Cincotta | Process for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia and hypoglycemia in vertebrates |
| US5792748A (en) * | 1995-06-07 | 1998-08-11 | The General Hospital Corporation | Method for inhibiting neoplastic disease in mammals |
| US6017914A (en) * | 1997-09-03 | 2000-01-25 | Eli Lilly And Company | Benzo[b]thiophene compounds, intermediates, formulations, and methods |
-
1997
- 1997-04-15 CA CA002253207A patent/CA2253207C/en not_active Expired - Fee Related
- 1997-04-15 EP EP97922668A patent/EP0910365B1/en not_active Expired - Lifetime
- 1997-04-15 WO PCT/US1997/007577 patent/WO1997040829A1/en not_active Ceased
- 1997-04-15 DK DK97922668T patent/DK0910365T3/da active
- 1997-04-15 AT AT97922668T patent/ATE243513T1/de active
- 1997-04-15 DE DE69723077T patent/DE69723077T2/de not_active Expired - Lifetime
- 1997-04-15 JP JP9539270A patent/JP2000509398A/ja active Pending
- 1997-04-15 ES ES97922668T patent/ES2205215T3/es not_active Expired - Lifetime
-
1998
- 1998-11-06 US US09/187,768 patent/US20010049350A1/en not_active Abandoned
-
2003
- 2003-11-21 US US10/719,534 patent/US20040102383A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2253207A1 (en) | 1997-11-06 |
| US20010049350A1 (en) | 2001-12-06 |
| US20040102383A1 (en) | 2004-05-27 |
| DE69723077T2 (de) | 2004-05-06 |
| JP2000509398A (ja) | 2000-07-25 |
| EP0910365A4 (en) | 1999-12-01 |
| CA2253207C (en) | 2008-12-30 |
| ATE243513T1 (de) | 2003-07-15 |
| ES2205215T3 (es) | 2004-05-01 |
| EP0910365B1 (en) | 2003-06-25 |
| DE69723077D1 (de) | 2003-07-31 |
| WO1997040829A1 (en) | 1997-11-06 |
| EP0910365A1 (en) | 1999-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK0910365T3 (da) | Væksthæmning og udslettelse af faste tumorer ved at anvende en prolactinmodulator og en fotosensibilisator | |
| AU732673C (en) | Device for the photodynamic treatment of living beings and of the organs thereof | |
| DK1083899T3 (da) | Derivater af 1-dexoy-galactonojirimycin og anvendelse heraf i behandlingen af lysosomale oplagringssygdomme ved øgning af lysosomal alpha-galactosidase A | |
| ATE277515T1 (de) | Verfahren zur behandlung von pigmentierten krebszellen durch photodynamische therapie | |
| NO984163D0 (no) | Forbedret syn ved fotodynamisk terapi av öyet | |
| AR022583A1 (es) | Secuencias antitumorales anti-sentido dirigidas contra los componentes r1 y r2 de la reductasa de los ribonucleotidos | |
| DK0912192T3 (da) | Administration af GM-CSF til behandling af hjernetumorer og forebyggelse af sådanne tumorers tilbagevenden | |
| ATE258486T1 (de) | Holzbehandlungsverfahren | |
| NO20002412D0 (no) | FremgangsmÕte for behandling av tumorer og tumorceller ved anvendelse av ex vivo aktiverte T celler | |
| DK0971710T3 (da) | Anvendelse af chelerythrin og stråling til tumorterapi | |
| RU94007018A (ru) | Способ лечения больных хроническим простатитом | |
| EA199900091A1 (ru) | Терапевтическое применение t-bam(cd40l)-технологии для лечения заболеваний с участием клеток гладкой мускулатуры | |
| NO20012311D0 (no) | Fremgangsmåte for å forebygge og helbrede aterosklerose hos pattedyr | |
| FI972953A0 (fi) | Menetelmä siirteen hylkäämisen estämiseksi | |
| ATE480571T1 (de) | Verwendung von maleimidderivaten in wasserverträglichen energie-härtbaren zusammensetzungen | |
| SU1424634A1 (ru) | Способ радиационной обработки транзисторов | |
| ES2148874T3 (es) | Composicion antioxidante y metodo para su produccion. | |
| SU1091396A1 (ru) | Способ лечени хронического неспецифического простатита | |
| RU95101096A (ru) | Способ лечения хронических простатитов | |
| RU96103517A (ru) | Способ определения индивидуальной дозовой нагрузки при надсосудистом лазерном облучении крови | |
| KIM et al. | Photodynamic therapy for early tongue cancer | |
| RU96120233A (ru) | Способ лечения переднего отдела глаза | |
| SU1187831A1 (ru) | Способ лечени желтухи новорожденных | |
| NO863454L (no) | Fremgangsmaate ved injeksjon av vann i underjordiske formasjoner. | |
| RU96114495A (ru) | Способ лечения больных с пароксизмальной атриовентрикулярной узловой ри-ентри тахикардией |